Feasibility of the assessment of ventricular function in patients with an exacerbation of COPD, within 24 hours of admission

Feasibility of the assessment of ventricular function in patients with an exacerbation of COPD, within 24 hours of admission - Ventricular dysfunction in exacerbation of COPD. EXACT-study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON31482

Enrollment

Registered

2008-03-04

Start date

2008-09-26

Completion date

Unknown

Last updated

2024-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic bronchitis emphysema

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients with COPD, aged 65 years or over, who experience an exacerbation for which admission to the hospital is necessary.

Exclusion criteria

Exclusion criteria: Patients with COPD, already known with a diagnosis of heart failure (assessment including echocardiography), patients unable or unwilling to give written informed consent, patients experiencing an exacerbation of COPD, however aged less than 65 years.

Design outcomes

Primary

Measure	Time frame
Participants will receive the usual investigations and treatment necessary in case of an exacerbation. After written informed consent, participants will additionally undergo a pulmonary function test including spirometry with flow-volume curves and echocardiographic assessment within 24 hours of admission. Left and right sided left ventricular function will be assessed. As is already common practice in the UMC Utrecht, blood tests will include measurements of plasma B-type natriuretic peptide (BNP), and high sensitive C-reactive protein at admission and discharge. Echocardiography and blood analysis will be repeated before discharge (about 7 days after admission). Echocardiographic and spirometric measurements will be performed at the bed-side with mobile apparatuses at the time the patient is clinically stabilised. It is common practice in the pulmonary department of the UMC Utrecht to perform blood tests including measurements of C-reactive protein (CRP) and plasma B-type natriuretic peptide. Outcome measures: - How many echocardiograms and spirometric measurements could be performed completely and adequately? - Are the results of these measurements interpretable (using a mobile bed-side apparatus in patients experiencing dyspnoea)? -What is the median (with 25-75% interquartile range) on the visual analoge scale from 0-10, with 0= no burden at all, and 10= extremely burdensome? To provide participants the most optimal possible treatment, possibly including cardiovasvcular therapy, in all participants an expert panel will establish presence or absence of ventricular dysfunction or heart failure (i.e. ventricular dysfunction and symptoms indicative of heart failure). The panel consisting of 2 cardiologists, a pulmonologist and a general practitioner (10) will use all available diagnostic information including pulmonary function test, echocardiographic results, and plasma B-type natriuretic peptide levels. Earlier studies have shown that	—

Measure

Time frame

Participants will receive the usual investigations and treatment necessary in case of an exacerbation. After written informed consent, participants will additionally undergo a pulmonary function test including spirometry with flow-volume curves and echocardiographic assessment within 24 hours of admission. Left and right sided left ventricular function will be assessed. As is already common practice in the UMC Utrecht, blood tests will include measurements of plasma B-type natriuretic peptide (BNP), and high sensitive C-reactive protein at admission and discharge. Echocardiography and blood analysis will be repeated before discharge (about 7 days after admission). Echocardiographic and spirometric measurements will be performed at the bed-side with mobile apparatuses at the time the patient is clinically stabilised. It is common practice in the pulmonary department of the UMC Utrecht to perform blood tests including measurements of C-reactive protein (CRP) and plasma B-type natriuretic peptide. Outcome measures: - How many echocardiograms and spirometric measurements could be performed completely and adequately? - Are the results of these measurements interpretable (using a mobile bed-side apparatus in patients experiencing dyspnoea)? -What is the median (with 25-75% interquartile range) on the visual analoge scale from 0-10, with 0= no burden at all, and 10= extremely burdensome? To provide participants the most optimal possible treatment, possibly including cardiovasvcular therapy, in all participants an expert panel will establish presence or absence of ventricular dysfunction or heart failure (i.e. ventricular dysfunction and symptoms indicative of heart failure). The panel consisting of 2 cardiologists, a pulmonologist and a general practitioner (10) will use all available diagnostic information including pulmonary function test, echocardiographic results, and plasma B-type natriuretic peptide levels. Earlier studies have shown that

—

Secondary

Measure	Time frame
none	—

Countries

Netherlands

Outcome results